Clinical Trial Update: Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B [Phase 3]

View source ↗

Summary

Phase 3 open-label, single-dose study evaluating CSL222 in adolescent males (ages 12 to under 18) with severe or moderately severe Hemophilia B; recruitment ong…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• CSL222

Snippet

Sponsor: CSL Behring | Conditions: Hemophilia B | Phase 3 | Status: RECRUITING